Table 1. Demographic and clinical information.
Data are represented as mean ± SD and n (%), or median (IQR). Student’s t-test, Chi-square test, Kruskal Wallis Test.
| Variable | Phenotype 1 (n = 57) |
Phenotype 2 (n=43) |
Phenotype 3 (n = 47) |
Phenotype 4 (n=46) |
p-val |
|---|---|---|---|---|---|
| Age, years | 44.35(8.03) | 45.86(8.96) | 46.11(7.95) | 45.3(8.7) | 0.7172 |
| Education, years | 12.91(3.07) | 12.44(2.68 | 13.11(2.24) | 13.5(2.07) | 0.2764 |
| Race/ethnicity, n (%) | 0.0598 | ||||
| White | 20(35.09) | 28(65.12) | 29(61.7) | 26(56.52) | |
| Black | 18(31.58) | 9(20.93) | 13(27.66) | 12(26.09) | |
| Hispanic | 16(28.07) | 5(11.63) | 4(8.51) | 5(10.87) | |
| Other | 3(5.26) | 1(2.33) | 1(2.13) | 3(6.52) | |
| Male, n (%) | 46(80.7) | 39(90.7) | 40(85.11) | 38(82.61) | 0.5677 |
| AIDS, n (%) | 42(73.68) | 31(72.09) | 36(76.6) | 32(69.57) | 0.9950 |
| Current CD4, median [IQR] | 391(423.25) | 487(390.75) | 360(355.75) | 517(349) | 0.0995 |
| Nadir CD4, median [IQR] | 126(182) | 127.5(206) | 72(181.5) | 97.5(261) | 0.4049 |
| Viral Load, median [IQR] | 115(13715) | 374(7247.25) | 409(7877.5) | 189(21547.75) | 0.8056 |
| Undetectable Viral Load, n (%) | 14(24.56) | 8(18.6) | 10(21.28) | 4(8.7) | 0.2096 |
| HCV, n (%) | 10(17.54) | 2(4.65) | 6(12.77) | 4(8.7) | 0.1668 |
| HIV Duration (years) | 12.41(6.7) | 13.51(7.9) | 11.51(6.09) | 12.78(6.49) | 0.5806 |
| Glucose, median [IQR] | 92.5(30) | 96(24.75) | 91(25.75) | 93(24.25) | 0.6979 |
| Cholesterol | 169.9(33.69)* | 192.44(47.52) | 196.14(42.47) | 176.95(37.15) | 0.0083 |
| CPE | 7.86(2.06) | 7.86(1.75) | 7.67(1.79) | 8.27(2.45) | 0.7448 |
| Baseline GDS-defined impaired, n(%) | 32(56.14) | 17(39.53) | 12(25.53) | 15(32.61) | 0.0121 |
| Follow-up GDS-defined impaired, n(%) | 26(45.61) | 19(44.19) | 17(36.17) | 19(41.3) | 0.7694 |
| Change Score: Verbal Fluency | −4.32(4.91)* | 0.62(5.36) | 2.43(5.32) | 1.94(5.22) | <0.0001 |
| Change Score: Executive Function | 4.13(6.99) | −10.93(6.3)* | 2.48(6.18) | −0.68(6.98) | <0.0001 |
| Change Score: Speed of Information Processing | 0.26(5.08) | 0.63(6.07) | −1.43(5.33) | −1.49(5.73) | 0.1336 |
| Change Score: Learning | 1.63(6.37) | 0.87(5.37) | −8.32(6.54)* | −1.3(6.94) | <0.0001 |
| Change Score: Recall | 2.54(6.76) | −1(7.6) | −8.54(6.82)* | 0.06(6) | <0.0001 |
| Change Score: Working Memory | 0.66(5.09) | 0.59(5.73) | −2.5(5.74)* | 0.26(6.91) | 0.0253 |
| Change Score: Motor | 0.04(5.28) | 1.81(5.54) | 0.83(7.25) | −9.62(4.97)* | <0.0001 |
| Lifetime MDD, n (%) | 20(35.09)* | 27(62.79) | 21(44.68) | 25(54.35) | 0.0286 |
| Lifetime Cannabis Abuse, n (%) | 7(12.28) | 6(13.95) | 13(27.66) | 7(15.22) | 0.1152 |
| Lifetime Cocaine Abuse, n (%) | 6(10.53) | 1(2.33) | 4(8.51) | 5(10.87) | 0.3623 |
| Lifetime Methamphetamine Abuse, n (%) | 1(1.75) | 2(4.65) | 1(2.13) | 2(4.35) | 0.7828 |
| Lifetime Hallucinogen Abuse, n (%) | 4(7.02) | 3(6.98) | 2(4.26) | 4(8.7) | 0.8394 |
| Lifetime Inhalant Abuse, n (%) | 1(1.75) | 1(2.33) | 1(2.13) | 2(4.35) | 0.8162 |
| Lifetime Opioid Abuse, n (%) | 1(1.75) | 0(0) | 1(2.13) | 0(0) | 0.6170 |
| Lifetime PCP Abuse, n (%) | 1(1.75) | 0(0) | 1(2.13) | 1(2.17) | 0.8014 |
| Lifetime Sedative Abuse, n (%) | 0(0) | 3(6.98) | 2(4.26) | 1(2.17) | 0.2573 |
| Baseline BDI, median[IQR] | 7[13] | 10[16] | 6[8.25] | 8.5[15] | 0.6772 |
| Follow-up BDI, median[IQR] | 6.5[2.5] | 10[12] | 9[9.5] | 9[15] | 0.4755 |
| PAOFI, median[IQR] | 1[5] | 3[10] | 1[5] | 3[7] | 0.4609 |
| Efavirenz, n (%) | 15(26.32) | 11(25.58) | 12(25.53) | 9(19.57) | 0.8585 |
| Atazanavir, n (%) | 15(26.32) | 14(32.56) | 14(29.79) | 9(19.57) | 0.5388 |
| Emtricitabine, n (%) | 21(36.84) | 18(41.86) | 25(53.19)* | 11(23.91) | 0.0343 |
| Ritonavir, n (%) | 21(36.84) | 18(41.86) | 24(51.06) | 15(32.61) | 0.2937 |
| Tenofovir, n (%) | 25(43.86) | 26(60.47) | 31(65.96) | 21(45.65) | 0.0708 |
| Abacavir, n (%) | 12(21.05) | 13(30.23) | 6(12.77) | 11(23.91) | 0.2419 |
| Zidovudine, n (%) | 13(22.81) | 4(9.3) | 7(14.89) | 9(19.57) | 0.3191 |
| Lopinavir, n (%) | 5(8.77) | 2(4.65) | 7(14.89) | 5(10.87) | 0.4260 |
| Lamivudine, n (%) | 28(49.12) | 15(34.88) | 13(27.66) | 20(43.48) | 0.1294 |
| Stavudine, n (%) | 5(8.77) | 1(2.33) | 3(6.38) | 2(4.35) | 0.5501 |
| Nevirapine, n (%) | 5(8.77) | 4(9.3) | 2(4.26) | 10(21.74)* | 0.0441 |